Calcipotriene/Betamethasone Dipropionate Cream vs Calcipotriol/Betamethasone Dipropionate Gel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: Vitamin D receptor + Glucocorticoid receptor · full Psoriasis pipeline
Calcipotriene/Betamethasone Dipropionate Cream · Wynzora
Marketed by MC2 Therapeutics
NCT03308799 · Phase 3 · completed
This randomized, investigator-blind Phase 3 trial gave calcipotriene/betamethasone dipropionate cream (MC2-01, Wynzora), CAL/BDP topical suspension or cream vehicle once daily for 8 weeks to 796 patients with psoriasis. The primary endpoint was PGA treatment success at week 8. The cream was significantly better than both the topical suspension (37.4% vs 22.8%) and the vehicle (3.7%), each P<0.0001, so the primary was met. Source: the peer-reviewed paper (Stein Gold et al., J Drugs Dermatol 2021), which cites this NCT number.
Reported efficacy
Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9) (unclear)
Result source: NCT03802344
Calcipotriol/Betamethasone Dipropionate Gel · Taclonex
Marketed by LEO Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Calcipotriene/Betamethasone Dipropionate Cream | Calcipotriol/Betamethasone Dipropionate Gel |
|---|---|---|
| PASI 75 | —Not reported | —Not posted · NCT00216827 |
| PASI 90 | —Not reported | —Not posted · NCT00216827 |
| PASI 100 | —Not reported | —Not posted · NCT00216827 |
| sPGA 0/1 | —Not reported | —Not posted · NCT00216827 |
| DLQI, change | —Not reported | —Not posted · NCT00216827 |
PASI 75
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriol/Betamethasone Dipropionate Gel
- —Not posted · NCT00216827
PASI 90
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriol/Betamethasone Dipropionate Gel
- —Not posted · NCT00216827
PASI 100
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriol/Betamethasone Dipropionate Gel
- —Not posted · NCT00216827
sPGA 0/1
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriol/Betamethasone Dipropionate Gel
- —Not posted · NCT00216827
DLQI, change
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriol/Betamethasone Dipropionate Gel
- —Not posted · NCT00216827
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Calcipotriol/Betamethasone Dipropionate Gel: no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Calcipotriene/Betamethasone Dipropionate Cream: 3 of 4 rows · Calcipotriol/Betamethasone Dipropionate Gel: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Calcipotriene/Betamethasone Dipropionate Cream |
|---|---|
| Dropout rate | 8.3% NCT03308799 · Phase 3 · Psoriasis · phase 3 show 1 more result3.8% NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3 |
| Discontinued due to AEs | — NCT03308799 · Phase 3 · Psoriasis · phase 3 show 1 more result— NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3 |
| Serious AEs | 3.3% NCT03308799 · Phase 3 · Psoriasis · phase 3 show 1 more result0.5% NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3 |
| Most frequent reported AEs | nasopharyngitis 4.7% (placebo 1.5%) NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Calcipotriene/Betamethasone Dipropionate Cream
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Calcipotriene/Betamethasone Dipropionate Cream's landscape · Calcipotriol/Betamethasone Dipropionate Gel's landscape